Patent Ductus Arteriosus (PDA) is a congenital cardiovascular anomaly characterized by the persistent patency of the ductus arteriosus, a vital fetal blood vessel that normally closes shortly after birth. This condition leads to abnormal blood flow between the pulmonary artery and the aorta, resulting in the mixing of oxygenated and deoxygenated blood. This can place undue stress on the heart, potentially causing complications such as heart failure if left untreated. Individuals with PDA may exhibit various symptoms, including but not limited to respiratory distress, inadequate weight gain, and an elevated susceptibility to respiratory infections. The clinical presentation can vary, and the severity of symptoms depends on the size of the patent ductus arteriosus. A prompt and accurate diagnosis is essential for effective management. Intervention options range from pharmacological approaches to surgical closure, with the choice depending on factors such as the patient's age, overall health, and the size of the ductus arteriosus. Medications that promote ductal closure or, in more severe cases, surgical procedures to physically seal the ductus arteriosus may be employed.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation